VANCOUVER, Washington, Oct. 08, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ('CytoDyn' or the 'Company'), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that Max Lataillade, DO, MPH, has been appointed as Senior Vice President and Head of Clinical Development. Under his consulting agreement, Dr. Lataillade will lead the Company's global research and development strategy and oversee end-to-end R&D activities to advance the Company's clinical development pipeline.

Dr. Lataillade brings over two decades of in-depth research experience to the CytoDyn team, with robust expertise investigating novel drug products and therapies. He most recently served as Vice President, Head of Early Development and Global Research Strategy at ViiV Healthcare, where he oversaw its novel HIV oral and long-acting pipeline. Prior to that, he was Vice President and Head of Global Development for HIV at Bristol-Myers Squibb, having joined the global clinical research group in 2007 as an infectious disease and HIV specialist. Dr. Lataillade is also currently an assistant clinical professor and teaching attending at the Yale University School of Medicine.